Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors ... Meanwhile, the U.S. Food and Drug Administration has approved BeiGene (NASDAQ:ONC)'s TEVIMBRA for use in combination ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

including Novartis and Beigene ($2.2 billion), AbbVie and I-Mab ($1.9 billion), and Seagen and RemeGen ($2.4 billion). More recently, Fortune reported Albert Bourla, CEO of Pfizer, as stating that ...

The removal of the dividend-paying requirement of all stock holdings has allowed the managers to cast a wider net and dip into growing Chinese firms like BeiGene ... took over as CEO in October ...

Delta CEO Ed Bastian spoke out on LinkedIn after a plane crash at Toronto-Pearson International Airport on Monday. "The hearts of the entire global Delta family are with those affected by today ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers. Ian Chan, CEO of Abpro, discusses the advantages of ...

Rigby, CEO, Epitopea, in a press release. “At Epitopea, we continue to accelerate the development of our preclinical pipeline as we transition to a clinical-stage company on the ‘heels’ of our recent, ...

The World EPA organisers have curated an exceptional programme featuring thought-provoking presentations and dynamic panel ...

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).